SCHEMBL20004724

SCHEMBL20004724

C#Cc1ccc(CN(C)C)o1

nearest known ligand 0.50

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACHE P22303 15/20 0.50
BCHE P06276 10/20 0.47
PRMT6 Q96LA8 1/20 0.42
CYP2A6 P11509 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.35
MYC P01106 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6214208 0.80 ACHE (0.50) ACHEBCHEPRMT6CYP2A6CYP2C19
SCHEMBL6827002 0.79 ALDH1A1 (0.36) ACHE
SCHEMBL2458150 0.78 ACHE (0.74) ACHEBCHEPRMT6CYP2A6CYP2C19
SCHEMBL22797395 0.77 ACHE (0.47) ACHEBCHEPRMT6CYP2A6CYP2C19
SCHEMBL21258306 0.77 ACHE (0.47) ACHEBCHEPRMT6CYP2A6CYP2C19
SCHEMBL15978536 0.77
SCHEMBL21258163 0.76 ACHE (0.46) ACHEBCHEPRMT6CYP2A6CYP2C19
SCHEMBL15244899 0.73 POLB (0.32) POLB
SCHEMBL9569265 0.72
SCHEMBL18265499 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112074507-B Compounds as Antibiotics 山东亨利医药科技有限责任公司 2023-09-05 CN disclosed
US-11498909-B2 Compound acting as antibiotics KBP BIOSCIENCES CO., LTD. (CN) 2022-11-15 US disclosed
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-02-02 US disclosed
US-20200392096-A1 COMPOUND ACTING AS ANTIBIOTICS KBP BIOSCIENCES CO., LTD. (CN) 2020-12-17 US disclosed
US-20200392096-A1 COMPOUND ACTING AS ANTIBIOTICS KBP BIOSCIENCES CO., LTD. (CN) 2020-12-17 US disclosed
EP-3750881-A1 COMPOUND ACTING AS ANTIBIOTICS KBP Biosciences Co., Ltd. (CN) 2020-12-16 EP disclosed
EP-3750881-A1 COMPOUND ACTING AS ANTIBIOTICS KBP Biosciences Co., Ltd. (CN) 2020-12-16 EP disclosed
EP-3515912-B1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NAT RECH SCIENT (FR) 2020-10-14 EP disclosed
WO-2019154412-A1 COMPOUND ACTING AS ANTIBIOTICS 山东亨利医药科技有限责任公司 2019-08-15 WO disclosed
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-07-11 US disclosed
WO-2018055316-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11498909-B2 Compound acting as antibiotics PEPD, NRDC, DPP4 ACHE 2761/4885BCHE 2210/4885PRMT6 3922/4885
US-20200392096-A1 COMPOUND ACTING AS ANTIBIOTICS PEPD, NRDC, DPP4 ACHE 2761/4885BCHE 2210/4885PRMT6 3922/4885
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases PSEN2, CLN6, MAPT ACHE 263/4885BCHE 344/4885PRMT6 2717/4885
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES PSEN2, SNCA, MAPT ACHE 307/4885BCHE 336/4885PRMT6 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.